Clinical trial
A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
NCT02989649 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
- Lead sponsor
- Takeda
- Phase
- Observational
- Overall status
- Terminated
- Start date
- December 22, 2016
- Completion date
- January 26, 2018
- Enrollment
- 593 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.